People · Operator
Named in public records as an officer, director or promoter · active 2011–2025 · Pharmaceuticals, Pharma, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Triana Biomedicines, Inc. | — | Pharmaceuticals | Series D+ | $178.6M | $852.1M | 2021 |
| Affinia Therapeutics Inc. | — | Pharma | Series D+ | $170.1M | $99.8M | 2020 |
| Xilio Therapeutics, Inc. | — | Biotechnology | Series C | $145.2M | $3.0B | 2021 |
| Arteaus Therapeutics, LLC | — | Biotechnology | Series B | $19.2M | $619.2M | 2011 |
| Annovation BioPharma, Inc. | — | Pharmaceuticals | Series A | $10.4M | $247.8M | 2011 |
| Akriveia Therapeutics, LLC | — | Biotechnology | Series A | $7.5M | $108.5M | 2018 |
David Grayzel at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Grayzel on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jean-Francois Formela | 2 | 17 |
| Robert Weisskoff | 2 | 12 |
| DAVID GARDNER | 1 | 20 |
| Michael Ross | 1 | 18 |
| ANDREW LEVIN | 1 | 17 |
| Joshua Resnick | 1 | 12 |
| Edward Mathers | 1 | 12 |
| Shelley Chu | 1 | 10 |
| Robert Johnson | 1 | 9 |
| Christopher O'Donnell | 1 | 8 |
| Thomas Beck | 1 | 7 |
| Daniel Lynch | 1 | 7 |
| Andrew Hack | 1 | 5 |
| Andrew Hedin | 1 | 5 |
| Lorence Kim | 1 | 5 |
| ANKIT MAHADEVIA | 1 | 4 |
| Milind Deshpande | 1 | 4 |
| Nancy Hong | 1 | 4 |
| Thomas Schuetz | 1 | 4 |
| Sean Nolan | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.